Connexin 32 (Cx32), a gap junction protein, is found within the para-nodal region and Schmidt-Lanterman incisures of myelinating Schwann cells (SCs). In developing and regenerating peripheral nerves, pro-myelinating SCs express Cx32 mRNA and protein in conjunction with the expression of myelin specific genes. Neuregulin-1 (Nrg1), a member of the neuregulin family of growth factors, controls SC proliferation and differentiation depending on the cellular environment and the particular stage of SC maturation. Primary cultures of purified SCs from newborn mouse sciatic nerve were used to characterize both the role of Nrg1 in the expression of Cx32 and, conversely, the role of Cx32 in SC responsiveness to Nrg1. Glial growth factor 2, an isoform of Nrg1, up-regulated Cx32 in both proliferating and non-proliferating SCs. However, SCs from Cx32-KO mice exhibited a significantly smaller mitogenic response to glial growth factor 2. Electrical coupling between Cx32-KO SCs did not differ from that between WT SCs, indicating the presence of other connexins. These results suggest a link between Cx32 expression and Nrg1 regulation of SC proliferation that does not involve Cx32-mediated intercellular communication.
I
n myelinating Schwann cells (SCs) of peripheral nerve, the gap junction protein connexin 32 (Cx32) is found within the non-compact myelin of the paranodal region and SchmidtLantermann incisures (1) . Cx32 gap junctions between successive cytoplasmic loops shorten the radial diffusion pathway for ions and other small signaling molecules between the SC nucleus and adaxonal cytoplasm at least 300 times (2) . Loss of Cx32-mediated coupling is thought to be the pathogenic mechanism in X-linked Charcot-Marie-Tooth disease (CMTX), an inherited peripheral neuropathy associated with mutations in the human gene for Cx32, GJB1 (3) . Supporting this idea, a mouse with targeted ablation of Cx32 develops histopathology resembling that seen in humans with CMTX (4) .
SC expression of Cx32 is not limited to the mature myelinating phenotype. Cx32 mRNA and protein are co-regulated with SC expression of myelin-specific genes during development and in regenerating peripheral nerves (1, 5, 6) . In mouse xenograft experiments, human nerve segments containing SCs with a predicted loss-of-function Cx32 mutation (Val181Ala) were severely impaired in their ability to support the earliest stages of regeneration of myelinated fibers, whereas nerve segments from a patient with a less severe mutation (Glu102Gly) and those from a normal subject supported normal early regeneration (7) . The abnormalities associated with the V181A mutation occur at a time when no myelin is present, further supporting a function for Cx32 in non-myelinating SCs.
Neuregulins, including Nrg1, Nrg2, and Nrg3, are a family of growth factors that influence the survival, differentiation, and myelinating potential of peripheral and central nervous system glial cells (reviewed in ref. 8) . ErbB2/ErbB3 heterodimers are neuregulin receptors and are required for SC development (9) . Nrg1 controls SC phenotype depending on cellular environment and the specific stage of SC differentiation or maturation (10) . Neuronal/axonal sources of neuregulin provide trophic support for immature SCs, promote myelin formation, and regulate myelin thickness during development (11) . In mature peripheral nerve, Nrg1 participates in the regeneration and re-myelination of injured myelinated fibers, processes that involve SC dedifferentiation, proliferation, and re-differentiation to a myelinating phenotype (12) .
Glial growth factor 2 (GGF2) is derived from a splice variant of the Nrg1 gene transcript. Isoforms of Nrg1, such as GGF2 and Nrg1-III, promote survival of cultures of SC progenitors (13) . GGF2 rescues cultured SCs after serum withdrawal and upregulates the expression of pro-myelinating SC markers (14, 15) . Furthermore, addition of GGF2 to myelinating co-cultures of SCs and sensory neurons causes demyelination and stimulates SC de-differentiation and proliferation (12) .
Primary cultures of purified SCs from newborn mouse sciatic nerve were used to characterize the role of GGF2 in SC expression of Cx32 and to determine whether expression of Cx32 alters SC responsiveness to it. We found that Cx32 expression was up-regulated by GGF2 and that GGF2 stimulated Cx32 expression in proliferating SCs as well as in non-proliferating SCs. These results suggest that Cx32 and GGF2 may interact through an amplification mechanism such that GGF2 increases expression of Cx32 in proliferating cells and Cx32 expressing cells are more sensitive to the proliferative effects of GGF2.
Cx32 KO cultures; and no significant differences were noted in BrdU labeling between control WT and 32KO SCs. To characterize the kinetics of 32KO SC proliferation and response to GGF2, Alamar Blue precursor was applied to control and GGF2-treated WT and 32KO cultures for up to 2 d after 6 DIV (Fig. S2) . Alamar Blue fluorescence is a measure of total cytoplasmic reducing capacity of metabolically active cells; however, over time the availability of reaction product may decline, affecting the linearity of the measurements (20) . At 7 DIV or 24 h after treatment, Alamar Blue signal was increased significantly in GGF2-treated WT SCs versus WT controls, in correlation with the increased proliferation at 7 DIV assayed by BrdU immunolabeling. By contrast, increases in Alamar Blue signal in response to GGF2 did not become significant in 32KO SCs until after 48 h of treatment (8 DIV) . Thus, the two measures of SC proliferation/metabolic activity were in qualitative agreement and demonstrated differences between WT and 32KO SCs in their responses to GGF2. Although decreased SC survival in 32KO cultures cannot be ruled out, visual inspection of WT and 32KO cultures at each time point did not indicate any alterations in cell morphology, nuclear fragmentation, cytoplasmic blebbing, increase in cellular debris, or any other sign of apoptotic or necrotic cell death. These findings are consistent with the hypothesis that loss of the Cx32 gene leads to attenuated mitogenic potential and a reduced proliferative response to GGF2, supporting a link between expression of Cx32 and Nrg1-mediated control of SC proliferation.
GGF2 Increases Cx32
Expression in Cultured SCs. The observation that SCs from 32KO mice show a reduced proliferative response to GGF2 raised the possibility that the GGF2 response may involve modulation of the expression of Cx32 in non-myelinating WT SCs. We used cultured SCs from neonatal WT mice to examine GGF2 modulation of Cx32. After 8 DIV, SC cultures were treated with 5 ng/mL GGF2, a concentration that gave a readily detectable response (Fig. S3) .
Treatment with GGF2 induced an increase in Cx32 immunofluorescence in cultured WT SCs ( Fig. 2 and Fig. S4 ) as a result of increase in both the amount of Cx32 per Cx32-positive cell (to 2.46 times control; Fig. 2 A) and the percentage of SCs labeled for Cx32 (to 1.25 times control; Fig. 2B ). Thus, the overall increase was to approximately 3 times control.
The affinity purified polyclonal anti-Cx32 antibody used in these studies (EL1, a gift from E. Hertzberg; see Methods) gave little or no staining of 32KO SCs, confirming its specificity (Fig.  S5 ). The specificity of 7c6.7c, a mouse monoclonal anti-Cx32 (a gift from E. Hertzberg, NY), was confirmed by Western blot analysis using WT and 32KO tissues and immunoprecipitation from lysates of cultured SCs (Fig. S6) .
Earlier studies characterizing the proliferative and differentiating effects of GGF2 used rat and mouse SCs grown and maintained in serum-containing media (21) . We found that GGF2 treatment of SC cultures maintained in serum-free B27NBM A also elicited up-regulation of Nrg1 receptors ErbB2 and ErbB3 (Fig. 3 ) (21) , increases that correlate positively with GGF2-stimulated increases in Cx32 as described earlier.
Proliferation and Expression of Cx32 in Cultured SCs. As described earlier, exposure to GGF2 increased WT SC labeling for BrdU by approximately 70% at 7 DIV, but did not alter BrdU labeling of SCs from 32KO mice (Fig. 1B) . We therefore examined the relation between GGF2-induced proliferation and Cx32 expression. After 6 DIV, WT SCs were treated overnight with BrdU with or without GGF2 and double-labeled for Cx32 and BrdU. GGF2 increased mean levels of Cx32 in both BrdU-positive (i.e., proliferating) and BrdU-negative (i.e., non-proliferating) cells, but more so in BrdU-positive cells (Fig. 4) . In addition, GGF2 treatment increased the percentage of total cells that were co-labeled for BrdU and Cx32 from 3.6% (30 of 838) to 6.5% (55 of 842; P ϭ 0.0073 Fisher exact test). These data are consistent with a relation between the mitogenic and Cx32-regulatory effects of Nrg1.
Forskolin Increases Cx32 Expression in Cultured SCs. GGF2 treatment of cultured SCs elevates intracellular levels of cAMP, and this response is associated with the mitogenic effects of GGF2 in either the presence or absence of serum (22) . Treatment with forskolin or cAMP analogs alone is not sufficient to promote proliferation in cultured SCs (23) . However, forskolin does promote expression of pro-myelinating SC markers P0, MBP, and MAG, genes whose SC expression correlates with that of Cx32 (24) . As observed with GGF2, Western blot analysis and Fig. 1 . GGF2 increases proliferation in WT SCs compared with 32KO. After 2 or 6 DIV, WT and 32KO cultured SCs were incubated with BrdU (10 M) overnight in the presence or absence of GGF2 (5 ng/mL) and fixed the next day at 3 DIV (A) or 7 DIV (B). (No. of images, 3 DIV, WT control, n ϭ 26; WT GGF2, n ϭ 16; 32KO control, n ϭ 27; 32KO GGF2, n ϭ 17; 7 DIV: WT control, n ϭ 25; WT GGF2, n ϭ 18; 32KO control, n ϭ 32; 32KO GGF2, n ϭ 21; **, P Ͻ 0.01, *, P Ͻ 0.05.) Nrg1 signaling involves protein kinase A (PKA)/cAMPmediated transduction pathways, among other well described cell signaling mechanisms (25) . To determine whether blockade of PKA signaling pathways would suppress the effects of GGF2 on Cx32 expression, WT SCs were pretreated for 30 min with PKA inhibitor peptide (PKAInh, a myristoylated cell-permeable specific PKA inhibitor peptide) or H8 (a less selective PKA inhibitor) followed by overnight treatment with inhibitor and GGF2 (5 ng/mL). PKAInh and H8 suppressed the effects of GGF2 on SC Cx32 (Fig. 5 ), indicating that PKA-signaling mediates GGF2 control of SC Cx32. Treatment with PKAInh blocked the effects of forskolin on Cx32 abundance, confirming the efficacy of the blocker and further demonstrating that Cx32 expression can be regulated directly through cAMP signaling pathways (Fig. S8 ). Whereas GGF2 and forskolin each stimulate Cx32 via cAMP/PKA-mediated transduction pathways, other Nrg1 subtypes might regulate Cx32 expression through additional ErbB2/ErbB3 signaling pathways.
GGF2 Regulation of Junctional
Coupling. Cx32-mediated coupling in proliferating SCs would be consistent with the concept that Cx32-mediated coupling is required for normal function of proliferating SCs, whereas Cx32 protein expression without coupling would suggest a non-junctional function in these cells. To examine this question further, junctional coupling was measured between isolated pairs of WT and 32KO SCs treated for 24 h with GGF2 or control medium after 1 to 9 DIV (Fig. 6) . Surprisingly, junctional conductance (g j ) between unstimulated WT and 32KO SC pairs did not differ significantly (2.5 Ϯ 0.5 nS, n ϭ 43 for WT; 1.78 Ϯ 0.5 nS, n ϭ 53 for 32KO). Moreover, GGF2 did not significantly increase the mean g j for either WT or 32KO cell pairs (2.2 Ϯ.1 nS, n ϭ 37 for WT; 2.6 Ϯ 0.8 nS, n ϭ 42 for 32KO). As with measurements of magnitude of conductance, evaluation of the trans-junctional voltage dependence and unitary conductances in the 4 groups of cell pairs showed no differences between WT and 32KO or between GGF2-treated and untreated cells. A range of single channel conductances was observed, not restricted to the Ϸ65 pS expected for Cx32. These data suggest that other connexins are likely to underlie the coupling in SCs (see Discussion).
Discussion. Here we show that SC expression of Cx32 is upregulated by treatment with the Nrg1 isoform GGF2; however, there is no corresponding increase in electrical coupling between SCs following exposure to GGF2. Remarkably, coupling conductance was not significantly different in any of the 4 groups: WT and 32KO with and without GGF2 treatment. In untreated controls, the percentage of SCs expressing Cx32 is similar in proliferating and non-proliferating subpopulations (BrdUpositive and BrdU-negative); however, treatment with GGF2 increases the level of expression more in proliferating than in non-proliferating SCs. Finally, SCs from 32KO mice show a striking absence of mitogenic response to GGF2 at 3 DIV and at 7 DIV, in contrast to the significant GGF2-stimulated increase in proliferation observed in WT cultures. These findings strongly suggest a role for Cx32 in Nrg1-mediated proliferation, but not one mediated by electrical coupling.
The experiments presented differ from many prior studies in that the SC cultures were grown and maintained in serum-free defined medium (after an initial period Յ24 h in bovine growth serum). Serum-free defined medium was used to preclude any effects from factors present in animal sera. For example, FBS is mitogenic for cultured SCs and alters responses to trophic factors (26, 27) .
The particular SC response to neuregulin involves a complex interplay between the differentiation state of the SC, the concentration and duration of Nrg1 exposure, and the resulting activation of multiple signaling pathways. Ligand activation of the ErbB2/ErbB3 receptor complex triggers elements in the PKA/cAMP, PI3K/Akt, and MAPK/ERK signaling pathways in proliferating and myelinating SCs (25, 28) . Inhibition of PI3K impedes SC proliferation, interferes with Nrg1 rescue of serum- Fig. 4 . GGF2 increases Cx32 expression in sub-populations of proliferating and non-proliferating cultured SCs. Dissociated WT SCs were seeded onto coverslips and, after 6 DIV, incubated overnight with BrdU (10 M) in the presence or absence of GGF2 (5 ng/mL). Cells were double-labeled with anti-Cx32 (EL1) and anti-BrdU and counterstained with DAPI. Cells were divided into BrdU-positive and BrdU-negative groups, and mean integrated Cx32 fluorescence per cell (in arbitrary units, see Methods) was determined for each group in control and GGF2-treated cultures. The relatively small population of BrdU-positive SCs showed significantly higher Cx32 signal per cell than the subpopulation of BrdU-negative/Cx32-positive SCs. (No. of cells: control BrdU-negative, n ϭ 358; GGF2 BrdU-negative, n ϭ 370; control BrdUpositive, n ϭ 30; GGF BrdU-positive, n ϭ 55; ***, P Ͻ 0.001, **, P Ͻ 0.01.) (No. of cells: control, n ϭ 1,242; GGF2, n ϭ 1,712; GGF2 ϩ PKAInh, n ϭ 1,314; GGF2 ϩ H8, n ϭ 1,392; ***, P Ͻ 0.001.) Fig. 6 . Gap g j does not differ significantly among WT and 32KO SCs with and without GGF2 treatment. Cells were maintained in B27NBM A for 1 to 9 DIV, treated overnight with GGF2 (5 ng/mL), and examined using dual whole-cell patch clamping. Untreated WT and 32KO sister cultures were examined in parallel. Cell pairs from all 4 groups show similar distributions of junctional coupling. Horizontal bars indicate mean g j .
deprived SCs, and inhibits the formation of myelin in SC-neuron co-cultures (24, 29) . Nrg1 treatment of myelinated co-cultures, however, causes profound demyelination and SC dedifferentiation and proliferation through phosphorylation of PI3K and MEK (30) .
Forskolin and cAMP analogues mimic some of the effects of axonal contact on SCs and induce SC differentiation toward a myelinating phenotype, including up-regulation of myelin proteins P0, MAG, and MBP, and down-regulation of nonmyelinating markers GFAP and N-CAM (23, 31) . We found that treatment with forskolin, which increases intracellular levels of cAMP, also enhances SC expression of Cx32. Increases in intracellular cAMP alone are not sufficient to stimulate SC proliferation, as neither forskolin nor cAMP is mitogenic for SCs grown without serum or other trophic agents (17) . However, forskolin significantly enhances the SC mitogenic responses to several growth factors, including Nrg1, PDGF, and insulin-like growth factor-1 (17, 23) . Forskolin also augments Nrg1-dependent SC proliferation by accelerating G1-to-S-phase cell cycle progression through stimulation of cyclin D, prolonged activation of ERK signaling, and increased PI3K/Akt activity (23, 32) . The effects of forskolin and Nrg1 involve common intracellular signaling cascades, including the MAPK and PI3K pathways. The balance of activities between these pathways appears crucial in modulating SC function.
Cx32 expression was significantly elevated in proliferating, BrdU-positive WT SCs following treatment with GGF2. In addition, inhibition of PKA suppressed the effects of both GGF2 and forskolin on Cx32. Inhibition of PKA hinders the proliferative effects of forskolin and can interfere with SC myelin formation in neuron/SC co-cultures (22, 33) . Monje and colleagues (34) recently reported that PKA activity has a synergistic gating action by enhancing GGF-mediated ErbB2/ErbB3 activation leading to SC proliferation. Although cAMP-mediated pathways appear to be involved in regulating both Cx32 and SC number and differentiation, it remains unclear whether these effects are directly associated with the same ErbB2/ErbB3 signaling pathways. We have shown that either forskolin or GGF2 can increase Cx32 expression, and that these agents exert their effects on Cx32 expression through PKA-mediated cell signaling pathways.
Nicholson and colleagues (35) described provocative findings suggesting WT and 32KO cultured SCs differ in their predominant phenotypic stage of development; specifically that 32KO SCs expressed high levels of GFAP, an early SC marker and indicator of non-myelinating phenotype. They also found that WT and 32KO SCs responded to treatment with GGF2 with increased proliferation at 8 to 12 DIV. We observed similar rates of BrdU incorporation in WT and 32KO SCs at 7 DIV. However, we found that treatment with GGF2 failed to stimulate proliferation in 32KO SCs. Closer examination suggests several differences. First, Nicholson and co-workers established cultured SCs in high serum (15%), which can lead to the generation of sub-populations of spontaneously immortalized SCs and a significant enrichment of de-differentiated SCs (55) . Second, the cultures were maintained in 2% serum, which contains growth factors that might interact with GGF2. Third, these SCs were isolated from Cx32-null mice with a mixed strain background. We have found distinct differences in rates of proliferation in SCs cultured from different mouse strains. For this reason, we used extensively back-crossed 32KO-C57BL/6 mice (provided by S.A.L. Bennett, Ottawa, ON, Canada) to eliminate possible strain effects. Despite these experimental differences, the observation that absence of the Cx32 gene leads to an increase in SC de-differentiation and deficit in responsiveness to differentiating signals is concordant with our observation of reduced mitogenic response to GGF2 in 32KO SCs.
Patch-clamp experiments showed no significant differences between the levels of junctional coupling in SC pairs from WT or 32KO mice, either with GGF2 stimulation or without. This implies that the absence of Cx32 has no impact on junctional coupling under these conditions. In addition, it supports the notion that any effect of Cx32 is likely to be independent of gap junction formation. In agreement with our results for GGF2, Chandross and colleagues showed no significant change in electrical coupling in response to treatment with neu differentiation factor-␤, a form of GGF (36) . Earlier reports of SC coupling differ from those reported here in the magnitude of coupling (36, 37) . However, species differences (e.g., rat vs. mouse), culture conditions (e.g., serum-containing vs. defined medium), as well as time in culture (e.g., up to 6 weeks vs. 2-10 d) may account for these divergent findings. Taken together, these findings suggest that Cx32 is entirely non-junctional in non-myelinating SCs and that presence of cytoplasmic Cx32 alters SC responses to the differentiating and proliferative effects of GGF2. Recent studies present intriguing associations for expression of non-junctional Cx32 and the control of proliferative capacity in some cell types. For example, phenobarbital promotes liver tumors rats and causes increased cytoplasmic Cx32 staining in centrolobular liver cells (38) . Increases in cytoplasmic Cx32 protein also favor hepatocellular carcinoma progression once the cells have acquired a malignant phenotype, further supporting an association between nonjunctional Cx32 expression and activation of cell cycle machinery (39, 40) .
The influence of Cx32 expression on cell proliferation appears to be cell type-specific. Loss of Cx32 expression appears to remove a level of regulatory control of cell cycle for tumor cells or pluripotent progenitor cells (41) (42) (43) . Melanson-Drapeau and colleagues (44) have observed an increase in oligodendrocyteprogenitor-cell proliferation in the dentate gyrus of Cx32-deficient mice. Cx32KO mice develop hepatic tumors at a rate much greater than WT. However, transgenic mice expressing a dominant-negative form of Cx32 (Val139Ala) show delayed liver regeneration and greater susceptibility to diethylnitrosamineinduced liver tumors. Exogenous expression of Cx32 suppresses proliferation in several cell lines (45, 46) . Finally, our findings suggest that Cx32 acts to promote proliferation in nonmyelinating SCs. Thus, expression of Cx32 can coordinate cell growth both positively and negatively and may be essential for homeostasis in certain cell types. Although Cx32 may be required for optimal growth in some cell types, it does not act exclusively as a suppressor or enhancer of growth, an idea first advanced by Omori and co-workers (40) .
Non-junctional actions of connexins include binding to other proteins and possibly acting as trafficking or scaffolding proteins (47) (48) (49) . In addition, connexins can form un-apposed hemichannels in non-junctional membranes and release such potential signaling molecules as ATP, IP3, NAD ϩ , and glutamate (48, 50) . CMTX mutations may act through increased opening as hemi-channels (51) .
The proposal that proliferation and Cx32 expression are regulated in parallel by GGF2 fits with the accepted role of Nrg1 in directing SC phenotype expression during developmental and regenerative processes (52) . In the mouse, Wallerian degeneration induces SC proliferation and increases expression of Nrg1 and ErbB receptors, with a maximal response at approximately 3 to 5 days after injury (53) . GGF and other Nrg1 isoforms, acting through neuronal (i.e., paracrine) and SC-mediated (i.e., autocrine) pathways, can stimulate SC survival and proliferation in response to denervation as suggested by previous molecular studies (54) .
We found that Cx32 is positively regulated by GGF2 in a population of proliferating and non-proliferating SCs. Moreover, in the absence of Cx32, SCs have a reduced mitotic response to GGF2 by 7 DIV. These results suggest a possible link between Cx32 expression and neuregulin regulation of SC proliferation. Our finding that GGF2 did not alter the expression of electrical coupling in proliferating SCs suggests that coupling across cells is not a mechanism for amplification of NRG-1 signaling. Unpublished findings from real-time PCR experiments suggest that other connexins are expressed in SCs and that some of these are also regulated by GGF2.* Further studies will be required to determine which connexins contribute to SC gap junction coupling.
Methods
Animals. Timed pregnant female C57BL/6 mice were obtained from Charles River Laboratories. Sciatic nerves were obtained from postnatal P3-5 day WT C57BL/6 mice. A colony of extensively backcrossed 32KO/C57BL6 mice (32KO) was bred in-house (founders provided by S.A.L. Bennett, Ottawa, ON, Canada). All animals were provided food and water ad libitum and housed according to the Guide for the Care and Use of Laboratory Animals. SC Cultures. SC cultures were established using a combination of standard methods (19, 32) , with some modifications as described in SI Methods. The dissociated SCs were transferred to B27NBM A [Neural Basal A Medium (Invitrogen); 0.5 mM GlutaMax (Invitrogen); 10 mM Hepes, pH 7.4; B27 supplement (Invitrogen); and Primocin (InvivoGen)] supplemented with 10% bovine growth serum (HyClone) and seeded onto polyD-lysine-coated dishes at 0.23 sciatic nerve equivalents/cm 2 supplemented with GGF2 (5 ng/mL' gift from Cambridge Neurosciences/Acorda) and forskolin (10 M; Sigma). Eighteen to 24 h after plating, cultures were switched to serum-free B27NBM A supplemented with GGF2 and forskolin. GGF2 and forskolin supplements were withdrawn when the cultures reached approximately 90% confluence at 4 to 5 DIV and maintained in B27NBM A alone thereafter.GGF2 and forskolin supplementation was always discontinued at least 24 h before any experimental treatment.
Immunocytochemistry. Cultures were fixed at room temperature with Histochoice (Amresco), permeabilized, and blocked with ICC block. Coverslips were processed for immunofluorescence as described in SI Text. Digital images were collected and analyzed using Metamorph 7 image analysis software (Molecular Devices) as described in SI Text.
Proliferation and Survival Assays. BrdU Incorporation. Cultures were treated with BrdU (10 M; Molecular Probes) overnight in the presence or absence of GGF2, fixed, and processed as described in SI Methods. Alamar Blue. Cultures were seeded onto black-wall, clear-bottom 96-well plates (Costar/Corning). Alamar Blue precursor (Invitrogen/Biosource) was added to a final concentration of 10% (vol/vol), along with GGF2 and buffer treatments. Alamar Blue fluorescence was read with a Flexstation II microplate reader (Molecular Devices).
Electrophysiology. Dual whole-cell patch clamping was performed as previously described on SC pairs 2 to 10 d after initial plating (7). Recording solutions were as follows: pipette solution, 145 mM CsCl, 5 mM EGTA, 0.5 mM CaCl2, 10.0 mM Hepes, pH 7.2; bath solution, 150 mM NaCl, 4 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 5 mM dextrose, 2 mM pyruvate, 10 mM Hepes, pH 7.4. Bars in Fig. 6 represent mean gj. 
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SI Methods
Animals. Timed pregnant female C57BL/6 mice were obtained from Charles River Laboratories. Sciatic nerves were obtained from postnatal day 3 to 5 WT C57BL/6 mice and cultured as described later. A colony of 32KO mice was bred in-house from Cx32-null founders (provided by S. Bennett, Ottawa, ON, Canada) that had been back-crossed at least 15 generations into C57BL/6 background. All animals were provided food and water ad libitum and housed according to the Guide for the Care and Use of Laboratory Animals.
SC Cultures. SC cultures were established using a combination of standard methods, with some modifications (1-3) . Briefly, sciatic nerves from postnatal day 3 to 5 neonatal mice were dissected and incubated in collagenase (2 mg/mL) and trypsin (0.125%) for 30 min at 37°C. The nerves were transferred to B27NBM A [Neural Basal A Medium (Invitrogen); 0.5 mM GlutaMax (Invitrogen); 10 mM Hepes, pH 7.4; B27 supplement (Invitrogen); and Primocin (InvivoGen)] supplemented with 10% bovine growth serum (HyClone). The nerves were gently dissociated with a Pasteur pipet and filtered through a 40-m nylon filter (Falcon). The dissociated SCs were seeded onto polyDlysine-coated dishes at 0.23 sciatic nerve equivalents/cm 2 in B27NBM A with 10% bovine growth serum and supplemented with recombinant human GGF2 (5 ng/mL; gift from Cambridge Neurosciences/Acorda) and forskolin (10 M). Eighteen to 24 h after plating, cultures were switched to serum-free B27NBM A supplemented with GGF2 and forskolin. GGF2 and forskolin supplements were withdrawn when the cultures reached approximately 90% confluence at 4 to 5 DIV and maintained in B27NBM A alone thereafter. GGF2 and forskolin supplementation was discontinued at least 24 h before any experimental treatment. The cultures are Ͼ99.5% pure by 2 days in culture as determined by morphology and immunostaining for p75NTR, S100, and CNPase.
For immunofluorescence, BrdU incorporation, and electrophysiology studies, SCs were plated onto polyD-lysine-treated no. 0 glass coverslips. For Alamar Blue studies, SCs were seeded into polyD-lysine-treated, clear-bottom 96-well plates (Costar).
Immunocytochemistry. Cultures were fixed at room temperature with Histochoice (Amresco), permeabilized, and blocked with ICC block (PBS, 2% BSA, 2% goat serum, 0.05% Tween-20, 0.1% fish gelatin, 0.1% Triton X-100). Coverslips were incubated in Image-IT (Invitrogen) and processed for immunofluorescence using standard techniques. Signal was detected with Alexa Fluor-conjugated secondary antibodies (Molecular Probes) and the coverslips were mounted using ProLong Gold plus DAPI (Molecular Probes). Digital images were collected using a Magnafire advanced imaging system (Olympus) and appropriate filters. Except where noted, images were obtained at magnification ϫ400. All images for a given data set were collected and processed in an identical manner. For each experiment, images from 3 to 4 random fields were collected for each coverslip, with at least 3 replicate coverslips per experimental group. Experiments were repeated at least 3 times. Values from cell-free areas were used to determine background for each image. Integrated fluorescence values were obtained from background-subtracted images using the cell scoring and multi-wavelength cell scoring applets in Metamorph 7 image analysis software (Molecular Devices). Thresholds were determined using negative control images, and cellular integrated fluorescence for these images (70-150,000 kDa; Sigma); normal goat serum (Sigma); and fish gelatin (Sigma). 
Supporting Experiments
GGF2 Concentration Response Relation. SC cultures were routinely treated with 5 ng/mL GGF2, which corresponds to approximately 5 times the EC 50 (1.13 ng/mL) for the proliferative effect of GGF2 preparation on rat SCs, as reported by the supplier (Acorda/Cambridge Neurosciences). Cultured (mouse) WT SCs were treated with increasing concentrations of GGF2 and assayed for Cx32 to establish a reasonable working concentration. Both normalized Cx32 immunofluoresce labeling (Fig. S3B) and Western blot analysis (Fig. S3A Inset) demonstrated a readily observable response at 5 ng/mL GGF2 with no response at 0.5 ng/mL and a decreased response at 20 ng/mL, consistent with desensitization. (There is another concentration response relation in (Fig. S7C) . Antibody Specificity. Little or no staining was detected in immunolabeled 32KO SCs, confirming the specificity of the affinity purified polyclonal anti-Cx32 antibody (EL1; a gift from E. Hertzberg) used in these studies (Fig. S5) . The specificity of 7c6.7c, a mouse monoclonal anti-Cx32 (a gift from E. Hertzberg, Bronx, NY) was confirmed by Western blot analysis using WT and 32KO tissues and immunoprecipitation from lysates of cultured SCs (Fig. S6) . Fig. S1 . Incorporation of BrdU is greater in control and GGF2-treated WT SCs than in control and GGF2-treated 32KO SCs. WT and 32KO cultured SCs at 6 DIV were incubated with BrdU (10 M) overnight in the presence or absence of GGF2 (5 ng/mL) and fixed the next day as described in SI Methods. BrdU-positive nuclei tended to be larger than BrdU-negative nuclei. Fig. S2 . WT SCs show greater rates of generation of Alamar Blue and more stimulation by GGF2 than 32KO SCs. WT and 32KO SCs were seeded onto 96-well plates as described in Methods. Fresh B27NBM A containing Alamar Blue precursor (10% vol/vol) with or without GGF2 (5 ng/mL) was added to the cultures at 6 DIV. Alamar Blue fluorescence was measured at 0.5, 16, 24, and 48 h after treatment (6) (7) (8) . Alamar Blue fluorescence is proportional to cell number and metabolic activity and is an index of cell viability and proliferation (4 -6). The table summarizes significance testing by ANOVA. (No. of replicate wells: n ϭ 24.) Fig. S3 . GGF2 increases SC expression of Cx32 in cultured SCs in a concentration-dependent manner. (A) Cultured WT SCs (after 9 DIV) were treated overnight with 0, 0.5, 5, or 20 ng/mL GGF2 and harvested for Western blot analysis. The blots were probed with monoclonal anti-Cx32 (7c6.7c) and were developed using chemiluminescent detection. There was a readily detectable response at 5 ng/mL and no response above control at 0.5 or 20 ng/mL. The figure represents 2 experiments. (B) WT SCs were seeded into 96-well plates and, at 9 DIV, were treated overnight with 0, 5, or 20 ng/mL GGF2 and immuno-labeled for Cx32 using affinity purified polyclonal antibody (EL1) and counterstained with Hoechst stain. Total Cx32 and Hoechst fluorescence signals were measured in a Flexstation II microplate reader (Molecular Devices). The Cx32 signal was normalized to the Hoechst signal and expressed in arbitrary units. (No. of wells per group: n ϭ 10; **, P Ͻ 0.01.) Fig. S4 . GGF2 increases expression of Cx32 in cultured SCs. WT SCs were plated on coverslips and, at 8 DIV, were treated overnight in control medium (Upper) or GGF2 (5 ng/mL, Lower). Cells were fixed and immuno-labeled with affinity purified polyclonal antibody to Cx32 (EL1; green) and counterstained with DAPI (red). The majority of SCs are spindle-shaped with the ovoid nucleus nearly filling the maximum cell diameter. Cx32 labeling was concentrated in the cytoplasm, and could form 2 triangular regions on either side of the nucleus (arrows). (Calibration bar: 25 m.) Fig. S5 . Immunolabeling of WT and 32KO cultured SCs demonstrates the specificity of the rabbit anti-Cx32 antibody used for the immunofluorescence studies in this study. WT and 32KO SCs were seeded onto polyD-lysine coated coverslips. Forty-eight hours after plating, the cells were fixed and processed for immunofluorescence using affinity-purified rabbit anti-Cx32 (EL1, 1:250) and mounted using Prolong Gold with DAPI (Molecular Probes). There was little or no labeling of 32KO cultures and extensive labeling of WT cultures. Similar results were seen in images from 3 replicates from each group. (Calibration bar: 50 m.) Fig. S6 . Western blot analysis and immunoprecipitation demonstrate the specificity of the monoclonal and polyclonal Cx32 antibodies used in these studies. (A) Liver and cortex (Ctx) were harvested from 6-week-old adult WT and 32KO mice. Twenty and 40 g of extract from each sample were loaded and separated on a 4% to 12% NuPage TrisBis gel (Invitrogen) and transferred and processed for Western blot using monoclonal mouse anti-Cx32 (7c6.7c, 1:2,000) and WestPico (Pierce) chemiluminescence detection. (B) Control-, GGF2-, and forskolin-treated cultured SCs were harvested for immunoprecipitation. Briefly, cells were harvested on ice in half-volume RIPA/LDS-1 with Complete protease inhibitor, and aliquots of total extract were taken. Following lysis, the samples were diluted with 2 volumes RIPA without LDS and pre-cleared with protein A/G Sepharose (Santa Cruz Biotechnology) at room temperature, and the supernatant was incubated overnight at 4°C with monoclonal anti-Cx32 (7c6.7c). Protein A/G Sepharose was added and the sample incubated further at room temperature. The beads were washed and eluted with IgG Elution buffer (Pierce) as recommended in the Seize Classic Immunoprecipitation protocol (Pierce). Total SC extract (25 g), eluted immunoprecipitation samples, and liver extract (10 g, Santa Cruz Biotechnology) were loaded and separated on a 10% NuPage gel. The gel was transferred and processed for Western blot using affinity-purified rabbit anti-Cx32 (EL1, 1:1000) and WestDura (Pierce) chemiluminescence detection. Immunoprecipitation resulted in significant recovery of the anti-Cx32 bound fraction. . GGF2 also increased the percentage of cells that were Cx32-positive at concentrations similar to those that were effective in increasing total Cx32 (Fig. S3) treatment. (No. of images: control, n ϭ 30; 2.5 M forskolin, n ϭ 14; 5 M forskolin, n ϭ 10; 10 M forskolin, n ϭ 9; for all concentrations of GGF2, n ϭ 4; *, P Ͻ 0.05, **, P Ͻ 0.01.) 
